We estimate that the CEO of HCA Healthcare, Inc. ($HCA), Samuel N. Hazen, received a compensation of $26,456,606 in 2025. This is an increase of 10.04% from an estimated $23,799,137 in 2024.
These estimates are based on a new DEF14A filing, filed with the SEC on March 13, 2026. Note that parsing errors may occur.
You can track $HCA on Quiver Quantitative's $HCA stock dashboard.
$HCA Stock Insider Trading Activity
$HCA Stock insiders have traded $HCA stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $HCA stock by insiders over the last 6 months:
- SAMUEL N HAZEN (CEO) has made 0 purchases and 7 sales selling 42,877 shares for an estimated $21,483,274.
- JENNIFER BERRES (SVP & Chief Human Res. Officer) has made 0 purchases and 2 sales selling 8,020 shares for an estimated $4,126,950.
- MICHAEL R MCALEVEY (EVP & Chief Legal & Admin Off.) has made 0 purchases and 2 sales selling 5,586 shares for an estimated $2,747,527.
- CHRISTOPHER F. WYATT (SVP & Controller) sold 4,000 shares for an estimated $2,020,000
- MICHAEL S. CUFFE (EVP and Chief Clinical Officer) sold 1,500 shares for an estimated $747,135
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$HCA Stock Hedge Fund Activity
We have seen 607 institutional investors add shares of $HCA Stock stock to their portfolio, and 671 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 5,306,304 shares (-77.3%) from their portfolio in Q4 2025, for an estimated $2,477,301,085
- FMR LLC added 1,928,240 shares (+101.2%) to their portfolio in Q4 2025, for an estimated $900,218,126
- BANK OF AMERICA CORP /DE/ removed 1,319,037 shares (-63.6%) from their portfolio in Q4 2025, for an estimated $615,805,613
- PACER ADVISORS, INC. removed 911,096 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $425,354,278
- NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO added 649,058 shares (+4545.5%) to their portfolio in Q4 2025, for an estimated $303,019,217
- JPMORGAN CHASE & CO removed 627,849 shares (-21.0%) from their portfolio in Q4 2025, for an estimated $293,117,584
- DIAMOND HILL CAPITAL MANAGEMENT INC removed 618,170 shares (-92.9%) from their portfolio in Q4 2025, for an estimated $288,598,846
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$HCA Stock Analyst Ratings
Wall Street analysts have issued reports on $HCA in the last several months. We have seen 12 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 01/28/2026
- Barclays issued a "Overweight" rating on 01/28/2026
- Oppenheimer issued a "Outperform" rating on 01/28/2026
- Truist Securities issued a "Buy" rating on 01/28/2026
- Deutsche Bank issued a "Buy" rating on 01/28/2026
- Morgan Stanley issued a "Underweight" rating on 12/15/2025
- Goldman Sachs issued a "Buy" rating on 10/27/2025
To track analyst ratings and price targets for $HCA Stock, check out Quiver Quantitative's $HCA forecast page.
$HCA Stock Price Targets
Multiple analysts have issued price targets for $HCA recently. We have seen 18 analysts offer price targets for $HCA in the last 6 months, with a median target of $550.5.
Here are some recent targets:
- Ryan Langston from TD Cowen set a target price of $561.0 on 03/10/2026
- Ann Hynes from Mizuho set a target price of $585.0 on 02/25/2026
- Andrew Mok from UBS set a target price of $635.0 on 02/23/2026
- Benjamin Rossi from JP Morgan set a target price of $535.0 on 02/20/2026
- David Toung from Argus Research set a target price of $560.0 on 02/06/2026
- Stephen Baxter from Wells Fargo set a target price of $481.0 on 01/30/2026
- Andrew Mok from Barclays set a target price of $551.0 on 01/28/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
